Andere talen Arcutis Biotherapeutics, Inc.

Aandelen

ARQT

US03969K1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:02 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,365 ^USD	-3,41%		-8,68%	+158,98%

15/05	ARCUTIS BIOTHERAPEUTICS, INC. : Needham & Co. herhaalt koopadvies	ZM
15/05	ARCUTIS BIOTHERAPEUTICS, INC. : Mizuho Securities bevestigt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ARCUTIS BIOTHERAPEUTICS, INC. : Needham & Co. reste à l'achat	15/05
ARCUTIS BIOTHERAPEUTICS, INC. : Mizuho Securities persiste à l'achat	15/05
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	15/05
Sector Update: Health Care	15/05
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket	15/05
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump	14/05
Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology	13/05
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	11/03
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	10/03
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	04/03
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	28/02
ARCUTIS BIOTHERAPEUTICS, INC. : Mizuho Securities toujours à l'achat	28/02
ARCUTIS BIOTHERAPEUTICS, INC. : Needham & Co. maintient sa recommandation à l'achat	28/02
Transcript : Arcutis Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	27/02
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
ARCUTIS BIOTHERAPEUTICS, INC. : Mizuho Securities optimiste sur le dossier	23/02
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	29/01
Transcript : Arcutis Biotherapeutics, Inc. - Special Call	22/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arcutis Biotherapeutics, Inc.

Aandelen

ARQT

US03969K1088

Andere talen

Filters